Qingdao Baheal Medical INC. (SHE:301015)

China · Delayed Price · Currency is CNY

22.15

+0.37 (1.70%)

At close: Mar 6, 2026

-5.78% (1Y)

Market Cap	11.64B
Revenue (ttm)	7.58B
Net Income (ttm)	527.03M
Shares Out	525.62M
EPS (ttm)	0.97
PE Ratio	22.85
Forward PE	19.26
Dividend	0.76 (3.44%)
Ex-Dividend Date	May 27, 2025

Volume	2,307,838
Average Volume	3,918,644
Open	21.71
Previous Close	21.78
Day's Range	21.68 - 22.25
52-Week Range	17.37 - 32.38
Beta	0.61
RSI	36.94
Earnings Date	Apr 29, 2026

About SHE:301015

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Harle, and Wei Xi Kang brand names. It also provides ophthalmic drugs under the HYCOSAN brand name; tumor and other severe drugs under the Human Albumin ... [Read more]

Industry Medical Distribution

Sector Healthcare

Founded 2005

Employees 3,064

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301015

Full Company Profile

Financial Performance

In 2024, SHE:301015's revenue was 8.09 billion, a decrease of -1.96% compared to the previous year's 8.26 billion. Earnings were 691.59 million, a decrease of -2.87%.

Financial Statements

News

There is no news available yet.